Latest News

GenPro adds Two Esteemed Scientists to Scientific Advisory Board

Who We Are

Genome Profiling, LLC (GenPro) is a molecular information company specializing in the discovery of novel epigenetic biomarkers based on our proprietary, genome-wide methylation profiling platform to revolutionize the way we treat, diagnose, and predict chronic and life-threatening diseases.

We are passionately committed to applying our scientific expertise in a revolutionary computational genetic-analysis technology to transform standard next-generation DNA sequencing data into actionable information that enables researchers and clinicians to make precision medicine a reality for patients afflicted with life-threatening diseases.

Grounded in leading scientific discoveries and an experienced life-science business team, GenPro provides quantitative biomarker analysis of DNA methylation profiles for personalized health diagnostics, disease prediction, and therapeutic monitoring. Central to our approach is a proprietary analytical and profiling software platform that transforms routine DNA genome sequence data into deep insights into the dynamic epigenome of individual patients. GenPro's pioneering discoveries in epigenetic profiling give us the distinctive ability to identify new and important biomarkers for specific disease states. Our epigenetic analysis results provide clinicians and researchers with actionable information that supports faster, more confident decision making and enables better outcomes for patient health.

What We Do

GenPro's quantitative analytics platform transforms the NGS value chain to yield novel epigenetic biomarkers that enable researchers and clinicians to tailor diagnostics and therapies to the needs of individual patients.

GenPro Analytics™, our proprietary, specialized software platform, employs genome-wide methylation profiling algorithms to discover novel epigenetic biomarkers that scientists and medical professionals can use to predict, diagnose, and monitor the likelihood and progression of disease in individuals with much more sensitivity, specificity, accuracy, and cost-effectiveness than any other approach available today.

Capitalizing on the exponential growth in next-generation sequencing (NGS) and the rising interest in and demand for epigenetic-profiling technologies and analysis of NGS data, GenPro Analytics™ drives transformational improvements across the entire NGS value chain while seamlessly integrating with current NGS pipelines and workflows. From reducing the cost, time, and complexity of preparing genomic DNA (gDNA) for sequencing to delivering highly sensitive and accurate quantitative whole-genome methylation profiles and novel epigenetic biomarkers, GenPro's cloud based analytical services enable biopharma, diagnostic, and NGS technology and service companies, and clinical-care research institutions, to achieve game-changing improvements in personalized disease prediction, diagnosis, and treatment.


The GenPro advantage starts with the simple addition of our gDNA prep kit to an existing whole-genome sequencing workflow. The restriction enzymes in this kit are matched to the GenPro Analytics™ methylation-profiling and biomarker-discovery software algorithms. Together, these technologies deliver results and provide answers that are superior to those obtained from the bisulfite oxidation approach typically used today. Our integrated technology:

  • Is simpler
  • Does not destroy any DNA
  • Delivers all the whole-genome sequencing data required for variant analyses
  • Is less expensive
  • Delivers unequalled quantitative methylation sensitivity and accuracy at all CpG sites
  • Requires only one NGS run, not two (half the cost)

As a result of these advances, researchers have access to highly sensitive, accurate, and comprehensive quantified methylation profiles for use in their own multivariate statistical analyses at a fraction of the cost of currently employed technologies. But more importantly, GenPro Analytics™ quantified methylation profiles enable previously unachievable downstream value generated by the discovery of novel epigenetic biomarkers that directly impact health improvements.

The most significant advantages of GenPro's technology are:

  • Versatility. From gDNA preparation using the GenPro gDNA prep kit through the discovery of novel epigenetic biomarkers using GenPro Analytics™, our portfolio of services comprises a single integrated solution that enables a superior standard NGS whole-genome sequencing strategy without chemically-induced (bisulfite oxidation) mutations. The NGS data produced from our technology can be used in standard genomic studies (SNPs, indels, alleles, etc.). But more importantly, we can derive a quantitative DNA methylation profile at each CpG location and extract from that data novel epigenetic biomarkers, something no one else can do as accurately, cost-effectively, or quickly.
  • Accuracy. GenPro's technology utilizes quantitative metrics for statistical processing. Our approach uses two lines of evidence in the raw sequence read files to reconstruct methylation status, resulting in more statistical confidence in our measurements for each CpG site.
  • Sensitivity. Statistical robustness and sensitivity are essential for biomarker discovery and diagnostic applications. Our approach is highly efficient in separating the epigenetic changes that signal shifts in health status from all the genomic noise and variability that exist between individuals.

GenPro Leadership Team

Jeb Connor - GenPro CEO and Co-Founder

Jeb Connor

Chairman, CEO and Co-Founder
Dr. Adam Marsh - GenPro Chief Scientific Officer and Co-Founder

Adam Marsh

Chief Science Officer and Co-Founder
Mort Goldman - GenPro Chief Technical Officer

Mort Goldman

Chief Technology Officer

Advisory Board

James Serum, PhD

Science and Business Strategy Advisor

Dr. Serum is formerly vice president of R&D at Agilent and founder of Agilent's bio-science business, Jim brings 43 years' experience in analytical diagnostics as a scientist, entrepreneur, VC partner, and federal science and technology policy advisor engaged with NAS and NIST. He served on the board of directors of numerous emerging technology companies at various stages of commercial development.

Tracy Shickel

Business Development and Strategy Advisor

Tracy brings over 20 years' experience in commercial operations leadership roles in life-science ventures within large companies including DuPont, Monsanto, WL Gore and Associates, and FMC Corporation.

Ian Wright, CBiol, MRSB

Science and Business Strategy Advisor

Ian moved from Siemens Healthcare Diagnostics, where he was VP, head of the Strategic Innovation group, to the position of CSO of the Advanced Clinical Bio-Systems Institute at Cedars-Sinai Medical Center. His career spans over 30 years in life-science commercialization and technology development.

GenPro and Helen F. Graham Cancer Center Present A Novel Epigenetic Biomarker Discovery Approach to a Potential Prognostic Marker for Triple Negative Breast Cancer at NAACR Conference in Washington DC on April 1-4, 2017

The work will be presented in a poster session at the NAACR Conference in Washington DC on Tuesday, April 4, 2017 from 8:00AM - Noon in the poster area in Halls A-C of the Convention Center. It is Section 15, Poster #30, Abstract #3369 which is part of the Epigenetics 3 Section of the Molecular and Cellular Biology & Genetics Session. The project is titled, "Epigenetic DNA Methylation Profiling of Triple Negative Breast Cancer: A Quantitative NGS Approach".

Read More

GenPro adds Two Esteemed Scientists to Scientific Advisory Board

Two renowned leaders in oncology epigenetics recently joined Genome Profiling’s (GenPro’s) Scientific Advisory Board. Christopher Mason, Ph.D., is Assistant Professor of Integrative Functional Genomics, Clinical Genetics and Synthetic Biology at Weill Cornell Medical College in New York. Ajay Goel, Ph. D. has also joined the GenPro Scientific Advisory Board. Dr. Goel is Professor and Director of Baylor Health's Scott and White Center for Gastrointestinal Research and the Center for Translational Genomics and Oncology.

Read More

GenPro publishes EpiMarker feasibility study revealing distinct epigenetic signature of Parkinson's Disease in blood.

Epigenetics is a rapidly developing field focused on deciphering chemical fingerprints that accumulate on human genomes over time. In this paper, GenPro reports a novel quantification methodology for computationally reconstructing site-specific CpG methylation status from next generation sequencing (NGS) data using methyl-sensitive restriction endonucleases (MSRE). In this pilot proof-of-concept study we quantify and compare DNA methylation in blood serum of individuals with Parkinson’s Disease relative to matched healthy blood profiles. Even with a small study of only six samples, a high degree of statistical discrimination was achieved based on CpG methylation profiles between groups, with 1008 statistically different CpG sites (p <0.0025, after false discovery rate correction). The future need for precision diagnostics now requires more tools for exploring epigenetic processes that may be linked to cellular dysfunction and subsequent disease progression. The paper, "Epigenetic DNA Methylation Profiling with MSRE: A Quantitative NGS Approach Using a Parkinson's Disease Test Case", is an open access publication and available at Frontiers in Genetics 2016:00191.

Read More

Contact Us